SS
ALDX icon

Sunbelt Securities’s Aldeyra Therapeutics ALDX Stock Holding History

Sunbelt Securities’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$10 – 2787
2025
Q3 		$10 Buy
+2
New +$10 ﹤0.01% 2683
2023
Q2 		– Sell
-100
Closed -$950 – 1695
2023
Q1 		$950 Buy
+100
New +$707 ﹤0.01% 1498

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sunbelt Securities's ALDX Position: Q4 2025 in Review

Sunbelt Securities sold out of Aldeyra Therapeutics (ALDX) in Q4 2025, closing a stake of 2 shares — an estimated $10 sold.

Sunbelt Securities first reported a position in ALDX in Q1 2023 and held it in 2 quarters. The position peaked at $950 in Q1 2023. 136 funds tracked by Wall St. Rank hold ALDX as of Q4 2025.

  • Sunbelt Securities reported no remaining Aldeyra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sunbelt Securities sold 2 Aldeyra Therapeutics shares in Q4 2025, an estimated $10.
  • Sunbelt Securities first reported a position in Aldeyra Therapeutics in Q1 2023 and held it in 2 quarters.
  • Sunbelt Securities's Aldeyra Therapeutics position peaked at $950 in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2025.

Based on Sunbelt Securities's 13F filing for Q4 2025, filed 20 Feb 2026.